Zentalis Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Zentalis Pharmaceuticals, Inc. has filed an amendment to its definitive proxy statement to correct a typographical error regarding the membership of its Nominating and Corporate Governance Committee ahead of the June 17, 2025 Annual Meeting.
NASDAQ
Zentalis Pharmaceuticals has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.
NASDAQ
DEF: Zentalis Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Zentalis Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, featuring director elections, auditor ratification, and executive compensation advisory vote.
NASDAQ
Zentalis Pharmaceuticals has appointed Dr. Luke Walker to its Board of Directors, increasing its size from six to seven members, effective May 24, 2024.
NASDAQ
Zentalis Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Zentalis Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 21, 2024, to vote on director elections, auditor ratification, and executive compensation.